Hopefully you got out of Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) early, as today the stock is trading 2.27% or 0.006 points down from last closing price of $0.26, reaching $0.2541 at last check. The TTNP share price has dropped in 4 of the last 5 days and is down -28.44% over the past week. It will be exciting to see whether the stock manages to continue decreasing or take a minor break for the next few days. The move came on weak volume too with far less shares changing hands than in a normal session. Trading activity as of this writing weakened by -9,225,217 shares, and in total 2.441 million shares valued at $620355 were seen changing hands compared with 11.667 million shares valued at $3.033 million recorded at the previous session. You should take into consideration that a falling volume on lower prices shows the bearish trend but this is an early indication which means that the TTNP stock is near its bottom.
Titan Pharmaceuticals, Inc. (TTNP) shares have notched a 3-month decline of about -28.44%, but has still advanced 35.5% year to date. By comparison, the stock sank -79.89% over the past 12 months, while it jumped 60.37% over the 1 month. The company’s market cap is around $19.38M, with its short interest ratio standing at 0.24%.
In the current trading session for TTNP, the stock witnessed two major price actions, it rose to a high of $0.2597 and was down as much as $0.245 at one point. The high recorded is very low when compared to their 52-week high which is $0.14. The 52-week high is now at -89.67 distance from current price. Their recent low of $2.45 represents a 78.24% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for TTNP is $8.5, this is above the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.
The stock of Titan Pharmaceuticals, Inc. earned $-1.53 per share in the trailing 12 months and has a P/E ratio of -0.17. You can compare it with that of similar companies in its industry to get a sense of whether the stock you’re looking to purchase is overvalued or undervalued. Its current price to earnings ratio is lower than the ones recorded by the industry which is and lower compared to the sector’s average of . When the P/E ratio is low let’s say below 1.0, then the stock price is considered a good value. TTNP also has P/S multiple of 5.2. This is greater versus the 12 month P/S ratios of other companies in the same indutry. The peer average price to sales ratio is x.
TTNP‘s last price was down -67.89% as compared to the average trading price of 50 days recorded at $0.79 while enlarging the period to 200 trading days, the average closing price was $0.19. At present, there are 73.7 million in the total number of common shares owned by the public and among those 66.3 million shares have been available to trade. The percentage of shares being held by the company management was 0.49% while institutions stake was 6.2%. The company has generated negative returns on equity over the last 12 months (-962.9%). It managed to keep its gross profit margin at 71.7% over the past 12 months.
When assessing the full upside of the TTNP stock, there is another set of technicals that should be looked into and considered. Its 17.66% gain from moving average of $0.22 has brought about a positive sentiment when calculated over the last 20 days. The market has allocated a beta of 1.29 to the stock. With the beta been greater than one, this implies that the company shares are theoretically more volatile than the market, something that the traders definitely are keeping an eye on.
Most of the analysts surveyed by Thomson/First Call think quite highly of Titan Pharmaceuticals, Inc. — 1 analysts rate the stock as a buy with another 0 rating it strong buy. There are 0 analysts who maintain a hold rating for the stock, with 0 giving it a sell rating. Analysts arrived at a 12-month price target of $1 on shares of Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), which corresponds to 296.83% upside potential than its current market price of $0.2541 and implies potential despite the recent drop in the price. However, their current target price has fallen from $1 a month ago and is down handily from the consensus target of $4 a quarter ago.
In the last five years, the EPS of the company has been roughly -17.1%. Though the percentage looks disappointing, extra headwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will decrease annually by 0%. The revenue of the company has retreated at an average annualized rate of about -8.8 over the last five years. The company recently recorded a drop of -47.1%, but this figure is rather unattractive.
Let’s briefly check the hedge fund interest towards TTNP stock. Vanguard Group Inc. added position in the company after it grew 23% or 473,317 shares of its common stock. The hedge fund now owns 582,180 shares worth $147,932, SEC documents show. A.R.T. Advisors LLC shored up assets in the stock as 26310.92 shares have been purchased, increasing its stake by 164.7% to 69,645 shares which are currently valued at $17,697. In addition, Perkins Capital Management Inc. recently reported that it now owns 90,838 shares making a total of $23,082 based on the recent price. This refelects a change of -83.3% in their ownership.